Marc Kozin

Our Company: Novel Treatments for Neuromuscular Disorders. Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated human efficacy related to muscle cramping. Novel Treatments for Neuromuscular Disorders, including Muscle Cramps. There is currently no proven or effective product for muscle cramps and spasms. Most muscle cramps are not caused by dehydration, lactic acid, electrolyte imbalance, or muscle tightness. That is why popular remedies like sports drinks, bananas, magnesium tablets, and stretching are usually ineffective. New research has shown that cramps and spasms do not originate in the muscle itself, but are caused instead by a neural mechanism: excessive firing of the motor neurons in the spinal cord that control muscle contraction. Flex Pharma is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Our founders include professors from Harvard Medical School and Rockefeller University (Nobel prize, 2003). Preliminary testing of Flex Pharma’s product in humans has shown that it can relieve electrically induced muscle cramps in minutes, and the effect lasts for hours.

Our Company: Novel Treatments for Neuromuscular Disorders. Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated human efficacy related to muscle cramping. Novel Treatments for Neuromuscular Disorders, including Muscle Cramps. There is currently no proven or effective product for muscle cramps and spasms. Most muscle cramps are not caused by dehydration, lactic acid, electrolyte imbalance, or muscle tightness. That is why popular remedies like sports drinks, bananas, magnesium tablets, and stretching are usually ineffective. New research has shown that cramps and spasms do not originate in the muscle itself, but are caused instead by a neural mechanism: excessive firing of the motor neurons in the spinal cord that control muscle contraction. Flex Pharma is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Our founders include professors from Harvard Medical School and Rockefeller University (Nobel prize, 2003). Preliminary testing of Flex Pharma’s product in humans has shown that it can relieve electrically induced muscle cramps in minutes, and the effect lasts for hours.

HealthCare Royalty ("HCRx") is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $5+ billion in more than 85 biopharma products since inception and has offices in Stamford (CT), San Francisco, Boston and London. The HCRx team consists of 33 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants. Our philosophy is simple - We are asset-focused investors seeking to identify compelling investment opportunities that will generate long-term value. We target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceuticals sectors. Our investment platform is designed to serve as a long-term capital resource for our partners; flexible and directly aligned with their business models and objectives. Our team utilizes multiple investment approaches to help our partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCRxs senior professionals have completed more than 60 healthcare investments. HEALTHCARE ROYALTY® IS A REGISTERED TRADEMARK OF HEALTHCARE ROYALTY MANAGEMENT, LLC.

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The companys drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocytes lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.